Adom, DjamilatouRowan, CourtneyAdeniyan, TitilayoYang, JinfengPaczesny, Sophie2020-07-312020-07-312020-04-21Adom, D., Rowan, C., Adeniyan, T., Yang, J., & Paczesny, S. (2020). Biomarkers for Allogeneic HCT Outcomes. Frontiers in immunology, 11, 673. https://doi.org/10.3389/fimmu.2020.00673https://hdl.handle.net/1805/23473Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) effect. Over the last decade, advances in “omics” technologies and systems biology analysis, have allowed for the discovery and validation of blood biomarkers that can be used as diagnostic test and prognostic test (that risk-stratify patients before disease occurrence) for acute and chronic GVHD and recently GVT. There are also predictive biomarkers that categorize patients based on their likely to respond to therapy. Newer mathematical analysis such as machine learning is able to identify different predictors of GVHD using clinical characteristics pre-transplant and possibly in the future combined with other biomarkers. Biomarkers are not only useful to identify patients with higher risk of disease progression, but also help guide treatment decisions and/or provide a basis for specific therapeutic interventions. This review summarizes biomarkers definition, omics technologies, acute, chronic GVHD and GVT biomarkers currently used in clinic or with potential as targets for existing or new drugs focusing on novel published work.en-USAttribution 4.0 InternationalBiomarkersGraft-versus-host diseaseGraft-versus-tumorHematopoietic cell transplantationProteomicsArticle